文献リスト

1) Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006; 41: 10-6

2) Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-30

3) Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1024-30

4) Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005; 353: 375-81

5) Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005; 353: 362-8

6) Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006; 354: 924-33

7) Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment？ Inflamm Bowel Dis. 2007, e-pub

8) Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-76

9) Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-11

10) Smolen JS, Han C, van der Heijde DMF, et al. Inflicimab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheumatism. 2006; 54: 716-22

11) Smolen JS, van der Heijde DMF, St. Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with or without concomitant infliximab. Arthritis Rheumatism. 2006; 54: 702-10

12) Goekkoop-Ruiterman YPMG, de Vries-Bouwstra, van Zeben D. Clinical and Radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheumatism. 2006; 54: 702-10

13) Goek-Ruiterman de Vries Bouwsttra JK, Allaart CF, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. Arthritis Rheumatism. 2006; 54: 3381-710

14) Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy (abstr). Gastroenterology. 2005; 129: 370

15) Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how？ Drugs. 2006; 66: 1431-9

16) Hyams JS, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-73

17) Oldenburg B, Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up？ Curr Opin Gastroenterol. 2007; 23: 395-9

18) Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastroenterology. 2006; 130: 323-33

19) Sandborn WJ, Rutgeerts P, Enns RA, et al. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN study (abst). Am J Gastroenterol. 2004; 99: 253

20) Colombel F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trail. Gastroenterology. 2007; 132: 52-65

21) Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-9. Epub 2007 Feb 13

22) Sandborn WJ, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. a randomized trial. Ann Intern Med. 2007; 146: 120

23) Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled study. Am J Gastroenterol. 2005; 100(Suppl S): S311

24) Sandborn WJ, Feagan BG, Stoninov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-38

25) Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-49

26) Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase II study (PRECISE 1) (abstr). Gastroenterology. 2006; 130(Suppl 2): A-107

27) Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129: 807-18

28) Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanized anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECISE) (abstr). Gut. 2005; 54(Suppl VII): A82

29) Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006; 35: 757-73

30) D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006; 8: 506-12

31) Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11: 465-71

32) Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641-57

33) D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006; 8: 506-12

34) Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007; 13: 2-11

35) Targan SR, Feagan BG, Fedorak RN, et al. International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007; 132: 1672-83. Epub 2007 Mar 21

36) Chaudhuri A. Selective adhesion-molecule therapy and inflammatory bowel disease. N Engl J Med. 2006; 354: 644-5

37) Podolsky DK. Selective adhesion-molecule therapy and inflammatory bowel diseaseーa tale of Janus？ N Engl J Med. 2005; 353: 1965-8

38) Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med. 2007; 46: 771-4. Epub 2007 Jun 1

39) Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI): - Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. Ann Rheum Dis. 2007 Jun 8; [Epub ahead of print]

40) D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006; 8: 506-12

41) Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005; 352: 2193-201

42) The American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007; 133: 312-39

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp